Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.78 Million CNY | -88.03% |
| 2022 | -3.07 Million CNY | 27.13% |
| 2021 | -4.22 Million CNY | 63.71% |
| 2020 | -11.62 Million CNY | -3994.01% |
| 2019 | -284 Thousand CNY | 38.13% |
| 2018 | -459 Thousand CNY | 76.49% |
| 2017 | -1.95 Million CNY | -123.17% |
| 2016 | 8.42 Million CNY | 6.2% |
| 2015 | 7.93 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -889.5 Thousand CNY | 72.92% |
| 2024 Q2 | -889.5 Thousand CNY | 0.0% |
| 2023 Q2 | -941 Thousand CNY | -83.07% |
| 2023 Q4 | -3.28 Million CNY | -215.26% |
| 2023 Q1 | -514 Thousand CNY | 79.6% |
| 2023 Q3 | -1.04 Million CNY | -10.73% |
| 2023 FY | -5.78 Million CNY | -88.03% |
| 2022 Q2 | -260 Thousand CNY | 61.82% |
| 2022 Q1 | -681 Thousand CNY | 63.7% |
| 2022 FY | -3.07 Million CNY | 27.13% |
| 2022 Q3 | 386 Thousand CNY | 248.46% |
| 2022 Q4 | -2.52 Million CNY | -752.85% |
| 2021 Q4 | -1.87 Million CNY | -535.93% |
| 2021 FY | -4.22 Million CNY | 63.71% |
| 2021 Q3 | -295 Thousand CNY | 67.22% |
| 2021 Q2 | -900 Thousand CNY | 21.67% |
| 2021 Q1 | -1.14 Million CNY | 77.13% |
| 2020 Q4 | -5.02 Million CNY | -915.15% |
| 2020 Q3 | -495 Thousand CNY | 85.24% |
| 2020 Q2 | -3.35 Million CNY | -21.83% |
| 2020 Q1 | -2.75 Million CNY | -37.31% |
| 2020 FY | -11.62 Million CNY | -3994.01% |
| 2019 Q4 | -2 Million CNY | -233.85% |
| 2019 Q3 | 1.49 Million CNY | 303.77% |
| 2019 Q2 | 371 Thousand CNY | 350.68% |
| 2019 FY | -284 Thousand CNY | 38.13% |
| 2019 Q1 | -148 Thousand CNY | 96.64% |
| 2018 Q3 | 1.91 Million CNY | -15.25% |
| 2018 Q4 | -4.41 Million CNY | -329.93% |
| 2018 FY | -459 Thousand CNY | 76.49% |
| 2018 Q2 | 2.26 Million CNY | 1083.91% |
| 2018 Q1 | -230 Thousand CNY | 0.0% |
| 2017 FY | -1.95 Million CNY | -123.17% |
| 2016 FY | 8.42 Million CNY | 6.2% |
| 2015 FY | 7.93 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 105.505% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 100.308% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 96.452% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 62.347% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 89.03% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | 134.627% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 102.101% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 79.954% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 94.549% |
| SSY Group Limited | 1.31 Billion HKD | 100.438% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 104.432% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 102.166% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 100.15% |